True North was a private equity fund that specialized in the growth and buyout of mid-market, India-centric companies. The leadership team initially believed that technology was not core to traditional businesses and steered clear of new age technology-oriented businesses. Then, in 2007, True North invested in Meru Cabs, a ride-sharing service with a growing fleet of cabs that had to change its business model with the launch of tech-based platforms like Uber. This experience led True North to significantly alter its stance on the importance of technology-powered business models. The team learned that all businesses needed to effectively become technology businesses to remain relevant. True North initiated the "Analytics, Algorithms and Artificial Intelligence" (3A) project. A system, Kelp, was designed and developed internally to facilitate the transformation of True North into an AI-first firm based on the introduction of data-driven decision making and productivity-enhancing digital tools. In 2020, as different elements of Kelp were launched, the leadership team met to discuss the future of this technology.

In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19. The case explores how a company builds a digital organization, and leverages artificial intelligence and other digital resources to speed its operations, manage its processes and ensure quality across research, testing and manufacturing. Built from the ground up as such a digital organization, Moderna was able to respond to the challenge of developing a vaccine as soon as the gene sequence for the virus was posted to the Web on January 11, 2020. As the vaccine enters Phase III clinical trials, Bancel considers several issues: How should Bancel and his team balance the demands of developing a vaccine for a virus creating a global pandemic alongside the other important vaccines and therapies in Moderna's pipeline? How should Moderna communicate its goals and vision to investors in this unprecedented time? Should Moderna be concerned it will be pegged as "a COVID-19 company?"